-
Trump claims 'infinite' Greenland security deal with Denmark
-
Anthropic picks Accenture for in-house AI safety evaluation
-
Helicopters battle wildfire threatening Ecuador's capital
-
Balogun returns as Monaco beat Lens to continue strong Ligue 1 start
-
Brentford batter Chelsea to undo Alonso's promising start
-
'Pause' on overt repression in Venezuela, but reforms still needed: HRW
-
Kane hits Bundesliga century as Bayern rout Union
-
Global stocks mixed as yen falls despite Bank of Japan rate hike
-
Trump says CNN, MS NOW, Politico banned from White House
-
Cuba hit with seventh major blackout of the year
-
Hushing and hedging: US companies retreat on climate
-
Murray out with concussion so Wentz will start for Vikings
-
Springboks to face Fiji before 2027 Rugby World Cup
-
UN chief 'deeply regrets' US visa refusal to Abbas for annual meeting
-
Nigeria miners struggled to breathe in cell before 37 died: survivors
-
England quick Carse to face no charges over alleged nightclub assault
-
McIlroy on the charge at PGA Championship as Reed withdraws
-
Mancini brings nine newcomers into the first squad of his Italy comeback
-
McIlroy on the charge at PGA Championship
-
Czechs level Davis Cup tie against USA as South Korea eye Finals
-
Crisis-wracked Volkswagen warns of 10-bn-euro hit to profits
-
New France boss Zidane confirms Mbappe as captain after naming first squad
-
Costa Rica's Grynspan tops third informal poll for UN chief: diplomat
-
California governor signs order to explore AI 'kill switch'
-
Stock markets retreat after central bank rate hikes
-
Head leads run spree as Australia win Zimbabwe ODI series
-
Russia labels director of Cannes Grand Prix winner a 'foreign agent'
-
In-form Raphinha wants to finish career at Barcelona
-
Macron warns of Russian 'hybrid' threat after meeting presidential hopefuls
-
Warren Buffett steps down as Berkshire Hathaway chairman
-
UN holds third informal poll for new chief
-
Carrick confident Man Utd can 'work through' tough time
-
Kulusevski return can spark Spurs: De Zerbi
-
Mbappe ends Nike partnership to join Swiss brand On
-
Shakira to cap off world tour with Madrid 12-gig run
-
Liverpool boss Iraola puts Bournemouth love affair on hold
-
Isolated Syrian-Druze city blames Damascus for shortages
-
'A disaster' if Man City do not win says Maresca after flawless start
-
Isolated Syrian-Druze city shortages
-
Kerry James Marshall: American 'blackness' painter celebrated in Europe
-
Dutch drop Depay for Germany match in Xavi's first pick
-
Spain coach De la Fuente offers 'full support' to people of Ceuta
-
Ronaldo named in Portugal squad for Nations League
-
Russia seizes assets of Nestle, French firms over West's Ukraine support
-
Stock markets diverge after central bank rate hikes
-
England can build on World Cup 'spirit', says Tuchel
-
Anti-Assad music star makes triumphant return to Syria
-
UNESCO can be 'moderator' in AI debate: chief to AFP
-
In-form Fernandez included in Spain Nations League squad
-
Infantino 'must go', says German FA vice-president
First person vaccinated during trial of new Ebola jab
A volunteer was injected on Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.
More than 1,000 people have been killed in the DRC and Uganda since the outbreak emerged in May, according to the World Health Organization.
Researchers and health organisations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage where it is tested on humans.
Earlier this month, a team at Oxford University in the UK announced it was launching the first trial for its ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca's Covid-19 vaccine.
The first dose was administered to a 37-year-old volunteer named Ed Hunt in Oxford on Friday, a university spokesman told AFP.
"We've taken this vaccine candidate from concept to clinic in just eight weeks," David Pulido-Gomez of Oxford's Pandemic Sciences Institute said in a statement.
"Reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort," he added.
The trial received funding from the Coalition for Epidemic Preparedness Innovations (CEPI), while the Serum Institute of India has already manufactured a stockpile of 620,000 doses.
The phase 1 trial plans to assess the safety and effectiveness of the vaccine in 50 health adults in the coming weeks. The researchers are currently recruiting more volunteers.
Given regulatory approval, the team is preparing for more clinical studies of the vaccine with partners in Uganda, Oxford said.
Several other Bundibugyo vaccine candidates are also being urgently developed towards the trial stage, while two potential treatments are being worked on.
The Ebola outbreak is the 17th in the DRC's history, but just the third caused by the Bundibugyo strain, for which there are no approved vaccines or treatments.
WHO chief Tedros Adhanom Ghebreyesus warned last week that the outbreak had over the past month "expanded faster than any previous outbreak" of Ebola.
The outbreak has remained concentrated in the vast country's mineral-rich and conflict-plagued northeastern province.
Cases of Ebola, which spreads through close contact and infected bodily fluids, have also been found in four other DRC provinces.
Q.Najjar--SF-PST